Xinyan Xu1,2, Lyu Huang1,2, Jiayan Chen1,2, Junmiao Wen1,2, Di Liu1,2, Jianzhao Cao1,2, Jiazhou Wang1,2, Min Fan1,2. 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Abstract
BACKGROUND: The purpose of this study is to develop a radiomics approach to predict brain metastasis (BM) for stage III/IV ALK-positive non-small cell lung cancer (NSCLC) patients. METHODS: Patients with ALK-positive III/IV NSCLC from 2014 to 2017 were enrolled retrospectively. Their pretreatment thoracic CT images were collected, and the gross tumor volume (GTV) was defined by two experienced radiation oncologists. An in-house feature extraction code-set was performed based on MATLAB 2015b (Mathworks, Natick, MA, USA) in patients' CT images to extract features. Patients were randomly divided into training set and test set (4:1) by using createDataPartition function in caret package. A test-retest in RIDER NSCLC dataset was performed to identify stable radiomics features. LASSO Cox regression and a leave-one-out cross-validation were conducted to identify optimal features for the logistic regression model to evaluate the predictive value of radiomics feature(s) for BM. Furthermore, extended validation for the radiomics feature(s) and Cox regression analyses which combined radiomics feature(s) and treatment elements were implemented to predict the risk of BM during follow-up. RESULTS: In total, 132 patients were included, among which 27 patients had pretreatment BM. The median follow-up time was 11.8 (range, 0.1-65.2) months. In the training set, one radiomics feature (W_GLCM_LH_Correlation) showed discrimination ability of BM (P value =0.014, AUC =0.687, 95% CI: 0.551-0.824, specificity =83.5%, sensitivity =57.1%). It also exhibited reposeful performance in the test set (AUC =0.642, 95% CI: 0.501-0.783, specificity =60.0%, sensitivity =83.3%). Those 105 patients without pretreatment BM were divided into stage III (n=57) and stage IV (n=48) groups. The radiomics feature (W_GLCM_LH_Correlation) had moderate performance to predict BM during/after treatment in separate groups (stage III: AUC =0.682, 95% CI: 0.537-0.826, specificity =64.4%, sensitivity =75.0%; stage IV: AUC =0.653, 95% CI: 0.503-0.804, specificity =70.4%, sensitivity =75.0%). Meanwhile, stage III patients could be divided into low risk and high risk groups for BM during surveillance according to Cox regression analysis (log-rank P value =0.021). CONCLUSIONS: We identified one wavelet texture feature derived from pretreatment thoracic CT that presented potential in predicting BM in stage III/IV ALK-positive NSCLC patients. This could be beneficial to risk stratification for such patients. Further investigation is necessary to include expanded sample size investigation and external multicenter validation. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: The purpose of this study is to develop a radiomics approach to predict brain metastasis (BM) for stage III/IV ALK-positive non-small cell lung cancer (NSCLC) patients. METHODS: Patients with ALK-positive III/IV NSCLC from 2014 to 2017 were enrolled retrospectively. Their pretreatment thoracic CT images were collected, and the gross tumor volume (GTV) was defined by two experienced radiation oncologists. An in-house feature extraction code-set was performed based on MATLAB 2015b (Mathworks, Natick, MA, USA) in patients' CT images to extract features. Patients were randomly divided into training set and test set (4:1) by using createDataPartition function in caret package. A test-retest in RIDER NSCLC dataset was performed to identify stable radiomics features. LASSO Cox regression and a leave-one-out cross-validation were conducted to identify optimal features for the logistic regression model to evaluate the predictive value of radiomics feature(s) for BM. Furthermore, extended validation for the radiomics feature(s) and Cox regression analyses which combined radiomics feature(s) and treatment elements were implemented to predict the risk of BM during follow-up. RESULTS: In total, 132 patients were included, among which 27 patients had pretreatment BM. The median follow-up time was 11.8 (range, 0.1-65.2) months. In the training set, one radiomics feature (W_GLCM_LH_Correlation) showed discrimination ability of BM (P value =0.014, AUC =0.687, 95% CI: 0.551-0.824, specificity =83.5%, sensitivity =57.1%). It also exhibited reposeful performance in the test set (AUC =0.642, 95% CI: 0.501-0.783, specificity =60.0%, sensitivity =83.3%). Those 105 patients without pretreatment BM were divided into stage III (n=57) and stage IV (n=48) groups. The radiomics feature (W_GLCM_LH_Correlation) had moderate performance to predict BM during/after treatment in separate groups (stage III: AUC =0.682, 95% CI: 0.537-0.826, specificity =64.4%, sensitivity =75.0%; stage IV: AUC =0.653, 95% CI: 0.503-0.804, specificity =70.4%, sensitivity =75.0%). Meanwhile, stage III patients could be divided into low risk and high risk groups for BM during surveillance according to Cox regression analysis (log-rank P value =0.021). CONCLUSIONS: We identified one wavelet texture feature derived from pretreatment thoracic CT that presented potential in predicting BM in stage III/IV ALK-positive NSCLC patients. This could be beneficial to risk stratification for such patients. Further investigation is necessary to include expanded sample size investigation and external multicenter validation. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: E J Limkin; R Sun; L Dercle; E I Zacharaki; C Robert; S Reuzé; A Schernberg; N Paragios; E Deutsch; C Ferté Journal: Ann Oncol Date: 2017-06-01 Impact factor: 32.976
Authors: Kimberley S Mak; Justin F Gainor; Andrzej Niemierko; Kevin S Oh; Henning Willers; Noah C Choi; Jay S Loeffler; Lecia V Sequist; Alice T Shaw; Helen A Shih Journal: Neuro Oncol Date: 2014-07-22 Impact factor: 12.300
Authors: Laure Fournier; Lena Costaridou; Luc Bidaut; Nicolas Michoux; Frederic E Lecouvet; Lioe-Fee de Geus-Oei; Ronald Boellaard; Daniela E Oprea-Lager; Nancy A Obuchowski; Anna Caroli; Wolfgang G Kunz; Edwin H Oei; James P B O'Connor; Marius E Mayerhoefer; Manuela Franca; Angel Alberich-Bayarri; Christophe M Deroose; Christian Loewe; Rashindra Manniesing; Caroline Caramella; Egesta Lopci; Nathalie Lassau; Anders Persson; Rik Achten; Karen Rosendahl; Olivier Clement; Elmar Kotter; Xavier Golay; Marion Smits; Marc Dewey; Daniel C Sullivan; Aad van der Lugt; Nandita M deSouza Journal: Eur Radiol Date: 2021-01-25 Impact factor: 5.315
Authors: Simon A Keek; Esma Kayan; Avishek Chatterjee; José S A Belderbos; Gerben Bootsma; Ben van den Borne; Anne-Marie C Dingemans; Hester A Gietema; Harry J M Groen; Judith Herder; Cordula Pitz; John Praag; Dirk De Ruysscher; Janna Schoenmaekers; Hans J M Smit; Jos Stigt; Marcel Westenend; Haiyan Zeng; Henry C Woodruff; Philippe Lambin; Lizza Hendriks Journal: Ther Adv Med Oncol Date: 2022-08-22 Impact factor: 5.485